On March 19, 2026, Aimed Alliance provided testimony to the New Jersey Prescription Drug Affordability Council, which is developing legislative and regulatory recommendations to address rising prescription drug costs. Aimed Alliance Staff Attorney, Olivia Backhaus, outlined why upper payment limits (UPLs) are unlikely to lower costs for patients, citing other states’ experiences with high administrative burdens, slow progress, and no consumer savings. The testimony emphasized that UPLs don’t guarantee reduced out‑of‑pocket costs, could raise premiums, and may create unintentional access issues. Instead, Aimed Alliance urged the Council to pursue targeted PBM reforms, which more directly address the drivers of high drug costs while maintaining patient access. Learn more about the NJ PDAC.
Last Updated on April 4, 2026 by Aimed Alliance
